How often does spontaneous remission occur in IgA nephropathy?
Spontaneous remission is surprisingly common in patients who receive only conservative (supportive) treatment. In a study of 62 adults with biopsy-proven IgA nephropathy who received no corticosteroids, immunosuppressants, or tonsillectomy, 39% achieved remission of proteinuria (defined as <0.3 g/gCr) and 31% achieved remission of both proteinuria and hematuria [5]. The median time to remission was about 2.6–2.8 years [5]. Another prospective study of 96 treatment-naive patients who received only optimized supportive care (ACE inhibitors or ARBs plus blood pressure control) found that 55% achieved remission (complete or partial) after 6 months, with 31% achieving complete remission (proteinuria <0.5 g/day) [2]. These figures show that spontaneous remission is not rare — it occurs in roughly one-third to one-half of patients managed conservatively.
Which patients are most likely to achieve spontaneous remission?
Patients with milder disease at diagnosis have the best chance. In the conservative-treatment study, remission rates were higher in patients whose initial proteinuria was below 0.5 g/gCr [5]. Those who achieved remission also tended to have preserved kidney function and lower blood pressure at baseline [5]. Conversely, patients who later experienced kidney function decline were older, had lower eGFR, and higher proteinuria at diagnosis [5]. A study of 39 patients found that higher expression of the COSMC gene (which helps produce normal IgA1) predicted remission, while more severe scarring on kidney biopsy (Oxford T score) predicted failure to remit [3]. So spontaneous remission is most realistic for patients with mild proteinuria, good kidney function, and less scarring on biopsy.
Does spontaneous remission protect the kidneys long-term?
Yes, sustained remission is strongly linked to better long-term kidney outcomes. A large multiethnic study of 1,864 patients found that each 3 months of sustained proteinuria remission (defined as ≥25% reduction to <1 g/day) reduced the risk of kidney failure or 50% eGFR decline by 9%, up to about 4 years of remission [4]. After 4 years, additional benefit leveled off, but the protective effect was already substantial [4]. In the conservative-treatment study, patients who achieved remission had stable kidney function during the first 3 years after diagnosis, while those who did not remit were more likely to lose kidney function [5]. However, even patients with normal proteinuria at diagnosis can sometimes decline, so ongoing monitoring is essential [5].
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2024, 1 from 2024 or later, 2 in Q1 journals, collectively cited 97 times — selected as the most relevant from 10 studies that passed quality screening, drawn from 44 papers retrieved from a database of over 500 million.
Sources used in this answer
Atrasentan in Patients with IgA Nephropathy
In a phase 3 randomized controlled trial of 340 patients, the endothelin receptor antagonist atrasentan reduced proteinuria by 38% versus 3% with placebo at 36 weeks, but this is not spontaneous remission — it is drug-induced.
Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study
In a prospective study of 96 treatment-naive patients on optimized supportive care (ACEi/ARB), 55% achieved remission (31% complete) at 6 months, showing that spontaneous remission with conservative therapy is common.
COSMC expression as a predictor of remission in IgA nephropathy
In a study of 39 patients, higher COSMC gene expression predicted remission (hazard ratio 1.87), while more kidney scarring (Oxford T score) predicted failure to remit, identifying a biomarker for spontaneous remission.
Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy.
In a retrospective multiethnic cohort of 1,864 patients, each 3 months of sustained proteinuria remission reduced the risk of kidney failure or 50% eGFR decline by 9% for up to 4 years, showing the long-term benefit of remission.
Spontaneous remission in adult patients with IgA nephropathy treated with conservative therapy
In a retrospective study of 62 adults on conservative therapy only, 39% achieved remission of proteinuria and 31% remission of both proteinuria and hematuria within a median of 2.6–2.8 years, with higher rates in those with mild proteinuria at diagnosis.